利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

37 条记录 (耗时 0.026 秒)

    SYSTEMS AND METHODS FOR COMPREHENSIVE ANALYSIS OF MOLECULAR PROFILES ACROSS MULTIPLE TUMOR AND GERMLINE EXOMES
    3.
    发明公开
    SYSTEMS AND METHODS FOR COMPREHENSIVE ANALYSIS OF MOLECULAR PROFILES ACROSS MULTIPLE TUMOR AND GERMLINE EXOMES 审中-公开
    系统和方法多肿瘤的遗传信息及政策分析KEIM TRACK EXOMEN

    公开(公告)号：EP3149641A1

    公开(公告)日：2017-04-05

    申请号：EP15799022.7

    申请日：2015-06-01

    申请人： Nantomics, LLC ,  Nant Holdings IP LLC

    发明人： RABIZADEH, Shahrooz ,  SOON-SHIONG, Patrick ,  SANBORN, John Zachary ,  VASKE, Charles Joseph ,  BENZ, Stephen Charles

    IPC分类号： G06F19/18 ,  G06F19/10

    CPC分类号： G06F19/18 ,  G06F19/22

    摘要： Omics patient data are analyzed using sequences or diff objects of tumor and matched normal tissue to identify patient and disease specific mutations, using transcriptomic data to identify expression levels of the mutated genes, and pathway analysis based on the so obtained omic data to identify specific pathway characteristics for the diseased tissue. Most notably, many different tumors have shared pathway characteristics, and identification of a pathway characteristic of a tumor may thus indicate effective treatment options ordinarily not considered when tumor analysis is based on anatomical tumor type only.

    摘要翻译： 组学的患者数据正在使用序列或肿瘤的差异的对象和匹配的正常组织，以确定患者和疾病特定突变分析，使用转录数据来识别所述突变的基因的表达水平，和途径分析基于如此获得的组学数据，以识别特异性途径 特性病变组织。 最值得注意的是，许多不同的肿瘤已经共享通路的特性，和肿瘤的途径特征的识别可以指示THUS有效的治疗选择通常不被认为是当肿瘤的分析是基于仅解剖肿瘤类型。

    CIRCULATING TUMOR CELL ENRICHMENT USING NEOEPITOPES
    7.
    发明公开
    CIRCULATING TUMOR CELL ENRICHMENT USING NEOEPITOPES 审中-公开

    公开(公告)号：EP3933408A1

    公开(公告)日：2022-01-05

    申请号：EP21192583.9

    申请日：2018-05-21

    申请人： Nant Holdings IP LLC

    发明人： RABIZADEH, Shahrooz ,  NIAZI, Kayvan ,  WITCHEY, Nicholas J.

    IPC分类号： G01N33/68 ,  G01N33/569 ,  C07K16/30

    摘要： An in vitro method of validating an immune therapy that targets a neoepitope of a tumor of a patient is described. The method comprises the steps of using a synthetic antibody against a tumor- and patient-specific neoepitope to enrich or isolate a cellular component carrying the tumor- and patient-specific neoepitope in a bodily fluid obtained from the patient; exposing the cellular component to a modified immune competent cell that expresses a chimeric protein or is coupled to an antibody, wherein the chimeric protein or antibody has binding specificity against the tumor- and patient-specific neoepitope; and detecting an immune response of the modified immune competent cell.